Integrated Systems and Technologies

In Vivo Imaging of Drug-Induced Mitochondrial Outer Membrane Permeabilization at Single-Cell Resolution

Sarah Earley¹, Claudio Vinegoni¹, Joshua Dunham¹, Rostic Gorbatov¹, Paolo Fumene Feruglio¹, and Ralph Weissleder¹,²

Abstract

Observing drug responses in the tumor microenvironment in vivo can be technically challenging. As a result, cellular responses to molecularly targeted cancer drugs are often studied in cell culture, which does not accurately represent the behavior of cancer cells growing in vivo. Using high-resolution microscopy and fluorescently labeled genetic reporters for apoptosis, we developed an approach to visualize drug-induced cell death at single-cell resolution in vivo. Stable expression of the mitochondrial intermembrane protein IMS-RP was established in human breast and pancreatic cancer cells. Image analysis was then used to quantify release of IMS-RP into the cytoplasm upon apoptosis and irreversible mitochondrial permeabilization. Both breast and pancreatic cancer cells showed higher basal apoptotic rates in vivo than in culture. To study drug-induced apoptosis, we exposed tumor cells to navitoclax (ABT-263), an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, both in vitro and in vivo. Although the tumors responded to Bcl-2 inhibition in vivo, inducing apoptosis in around 20% of cancer cells, the observed response was much higher in cell culture. Together, our findings show an imaging technique that can be used to directly visualize cell death within the tumor microenvironment in response to drug treatment. Cancer Res; 72(12); 2949–56. ©2012 AACR.

Introduction

A major obstacle in the development and monitoring of cancer treatments is determining how multiple biologic factors interact to control tumor responses to therapeutic drugs. In vivo imaging represents a powerful, noninvasive tool for revealing cellular responses through time and space. A prevailing challenge, however, has been understanding and quantitating the responses of both individual cancer cells and whole tumors to therapeutic drugs; namely, determining the distribution of drugs to cells, the extent and timing of cell death, and the impact of these cell-level responses on tumor regression. Recent advances in intravital microscopy have now enabled high-resolution in vivo imaging at the single-cell level. This technology potentially not only allows measurement of drug distribution and uptake into tumor cells (pharmacokinetics, PK; ref. 1) but also permits evaluation of downstream responses over different time scales (pharmacodynamics, PD). To visualize and measure in vitro drug responses in cells, a variety of fluorescent protein reporters have been developed; these include caspase cleavable fluorescent proteins [which can function either as fluorescence resonance energy transfer (FRET); ref. 2 or turn-on probes (ref. 3)], mitochondrial outer membrane permeabilization (MOMP) probes (2), senescence markers (4), and autophagy probes (5). The majority of these reporters, however, have only been tested in model cell lines and thus often fail to adequately reflect the primary tumors on which specific drugs are being tested in trials. Moreover, upon conversion or cell death, many of these reporters exhibit only subtle changes in fluorescence, which tend to be more difficult to measure in vivo due to motion artifacts, and (often) lower signal-to-noise ratios. In contrast, injectable imaging probes (Annexin V, synaptotagmin) have been used primarily for macroscopic imaging without clear microscopic correlates (6–8). There is thus a clear need for robust reporters that can consistently and reliably detect cell death in common tumor models undergoing treatment with novel targeted drugs.

To address this need, we reasoned that structural analysis of apoptotic tumor cells should be feasible in live animals provided that the resolution is sufficiently high to structurally resolve mitochondria in the cells of live mice. Using a previously described construct (2, 9) and cloning it into a lentiviral vector for greater efficiency, we created breast (MDA-MB-231) and pancreatic (PANC-1) cancer cell lines that stably express the intermembrane space reporter protein (IMS-RP GFP or mCherry). In steady-state cells, mitochondria are seen to contain IMS-RP. Upon apoptosis and irreversible mitochondrial permeabilization, IMS-RP is rapidly released from the spatially conserved intermembrane mitochondrial space into the cytoplasm, where it can be detected and quantified using automated image analysis or visual inspection. Using these
cancer models, we show not only that apoptosis can indeed be visualized in the tumors of live animals but also that apoptotic rates are markedly different in vitro versus in vivo (both temporally and fractionally). We also show that navitoclax monotherapy induces apoptosis in vivo in both breast and pancreatic cancer.

Materials and Methods

Cell culture

MDA-MB-231 human mammary carcinoma cells [American Type Culture Collection (ATCC)] were grown in RPMI media supplemented with 10% FBS, 1% L-glutamine, and 1% penicillin/streptomycin (Mediatech). PANC-1 human pancreatic adenocarcinoma (ATCC) cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS, 1% L-glutamine, 1% penicillin/streptomycin, and 2% sodium bicarbonate (Lonza). Cells expressing fluorescent reporters were grown in selection medium containing either 3 μg/mL puromycin or 10 μg/mL blasticidin S (Invitrogen). All cells were grown at 37°C and 5% CO2.

Cloning and lentivirus production

Mitochondrial intermembrane space reporter protein (IMS-RP) is an established reporter of MOMP; it contains the first 59 amino acids of Smac/DIABLO fused to a fluorescent protein (2). MOMP is a commitment step during apoptosis, and IMS-RP enables the visualization of this process at single-cell resolution in vitro, a fluorescent protein (pBABE IMS-RP) was generously provided by Drs. Peter Sorger and Timothy Mitchison (Department of Systems Biology, Harvard Medical School, Boston, MA), respectively. IMS-RP and histone H2B were subcloned into the pLVX-AcGFPI vector and pLVX-mCherry-N1 vectors using In-Fusion cloning (Clontech). Plasmids were verified by DNA sequencing (Genewiz).

For lentivirus production, LentiX-293T cells (Clontech) were transfected with pLVX-IMS-RP or pLVX-H2B and Lenti-X HTX Packaging Mix containing lentiviral packaging genes, using the Xfect transfection reagent and following the protocol recommended by the manufacturer (Clontech). Approximately 56 to 72 hours after transfection, the supernatant was collected, filtered using a 0.45-μm cellulose acetate syringe filter, aliquoted, and then snap-frozen in liquid nitrogen for storage at −80°C. All viral supernatants were used immediately upon thawing.

Generation of cell lines expressing reporters

Cells were transduced in 12-well plates using several dilutions of viral supernatant and 4 μg/mL polybrene per well (Invitrogen). Twenty-four to 48 hours after infection, cells were trypsinized and placed into medium containing 3 μg/mL puromycin. When generating double reporter cell lines, double-positive cells were sorted using the FACS Aria II (Becton Dickinson). Sorting was performed at the Harvard Stem Cell Core facility at MGH.

In vitro time-lapse microscopy

To determine the kinetics of apoptosis after drug treatment of cell lines in vitro, we used time-lapse microscopy; this enabled us to visualize apoptosis of single cells, within a population of cells. In vitro time-lapse microscopy was carried out using a DeltaVision imaging system (Applied Precision), which consists of an environmental chamber heated to 37°C, with CO2 bubbled through a water bath, an automated Olympus IX70 inverted microscope and a CoolSNAP HQ2 CCD camera. Cells were grown and imaged in ibidi 96-well plates (ibidi). Fields of view were chosen based on the equivalence of fluorescence intensity across the cell population (to avoid under/overexposure of cells) and on adequate cell density. Once fields of view were chosen, cells were treated with (i) 25 or 100 μM ABT-263 (Selleck Chemicals) in 0.5 or 2% dimethyl sulfoxide (DMSO) or (ii) vehicle only, and time-lapse imaging was initiated. Postacquisition images were visualized using Fiji/ImageJ 1.45r (NIH, Bethesda, MD) and analyzed for markers of apoptosis (MOMP, rounding, blebbing, chromatin condensation) either by eye or using MATLAB (MathWorks).

Mice

Nau/nu mice (Cox-7, Massachusetts General Hospital, Boston, MA) were housed and handled according to Massachusetts General Hospital Institutional Animal Care and Use Committee guidelines. For procedures involving window chamber and tumor implantation, intravenous injection, and intravital imaging, mice were anesthetized by isoflurane inhalation at a flow rate of 2 L/min isoflurane:2 L/min oxygen. For extended anesthesia, the isoflurane flow rate was gradually reduced to 1 to 2 L/min. All surgical procedures were carried out in a sterile surgery room using a stereomicroscope. For mice implanted with window chambers, antibiotics were administered via the drinking water. Anesthetized mice were monitored at all times. Titanium dorsal skin fold chambers (APJ Trading Co, Inc.) were surgically implanted in the dorsal skin fold of nau/nu mice, as described previously (1). Tumor cells (1:1 mixture of reporter to nonfluorescent parent cell) in a 1:4 mixture with Matrigel (Becton Dickinson) were injected subcutaneously into the window of the chamber and allowed to grow for approximately 1 week. The skin was removed and replaced with a 10-mm diameter glass coverslip, secured in place with a C-clip. For intravital experiments, mice were treated with 100 mg/kg ABT-263 (12.5% DMSO/PEG-400, 100 μL total volume) intraperitoneally once a day for 2 days.

Intravital microscopy

Anesthetized mice were positioned on a stable platform heated to 37°C with the dorsal window chamber mounted coverslip side facing up. Fluorescein isothiocyanate (FTTC)-dextran (Sigma Aldrich), Angiosense 680/750 (Perkin Elmer, Inc.), Annexin-Vivo 750 (Perkin Elmer, Inc.), or CLIO VT680 were administered via tail vein catheter. Tumors were imaged in vivo using a customized Olympus FV1000 BX61-W1 (Olympus America) confocal/multiphoton microscope with a programmable, motorized X-Y-Z stage. The objectives used were ×2/340 XLFluor (NA = 0.14, air), ×20 UPlanFL (NA = 0.50, water), and ×60 LUMPL N (NA = 1.10, water). AcGFP1 and mCherry were excited using the 488-nm line of an argon ion laser and a 559-nm diode laser, respectively. Emitted light was separated using a 405/488/559/635-nm
Image processing and analysis

Microscopy images from in vivo or in vitro experiments were processed using collaborative digital filtering (10) and alpharooting to simultaneously reduce noise and enhance image details. More details are reported in the Supplementary Material.

Analysis of time-lapse images was conducted using MATLAB (MathWorks) and Fiji/ImageJ 1.45r (NIH). Only unprocessed images were used for image analysis. Image analysis for automated MOMP detection was done on individual frames of time-lapse image stacks. Cell detection and segmentation were initially carried out using the bright-field images, from which segmentation masks around cells of interest could be created. Regions of interest (ROI) were then automatically selected within the cells, excluding areas of high-intensity signal (from mitochondria), to detect subtle changes in cytosolic intensity. Similarly sized ROIs were also selected from the background. Median intensity values for both cytosol and background ROIs were determined and normalized by their areas; background signal was then subtracted from the cytosol signal. From the plotted data, a sharp change in slope is clearly seen over time; this change corresponds to the point at which MOMP occurs.

Results

Characterization of cell lines

IMS reporter protein (IMS-RP) is a genetic reporter of apoptosis that was created by fusing a fluorescent protein to the first 59 N-terminal amino acids of the mitochondrial protein Smac/DIABLO (2, 9). During apoptosis-associated MOMP, the fluorescent protein is released from the IMS into the cytosol. Although IMS-RP contains the mitochondrial targeting signal peptide, it does not contain the inhibitor of apoptosis protein (IAP)-binding motif and is therefore biologically neutral. In cells transduced with IMS-RP GFP, fluorescence was observed within the mitochondria (Figs. 1 and 2), colocalizing with both full-length endogenous Smac/DIABLO and apoptosis-inducing factor (AIF), another protein that resides within the mitochondrial IMS (Supplementary Fig. S1). MDA-MB-231 cells typically showed filamentous mitochondria, which localized most abundantly around the nucleus (Fig. 1A). In contrast, PANC-1 cells typically contained shorter and more rounded mitochondria that were scattered throughout the entire cell (Fig. 2A). These mitochondrial phenotypes were consistent throughout all of our experiments, suggesting that the mitochondria of MDA-MB-231 and PANC-1 cells are morphologically distinct. In addition, IMS-RP fluorescence is brighter in the MDA-MB-231 cells, regardless of whether cells...
are transfected or transduced, which could influence the resultant images. Occasionally, round “swollen” mitochondria were seen in both cell lines, but the presence of these mitochondria did not correlate with apoptosis. In fact, recent findings suggest ill correlation between mitochondrial morphology and apoptosis, such that swollen or fragmented mitochondria do not predict apoptosis (11).

In cell culture, apoptosis occurred in approximately 0.6% of MDA-MB-231 cells and in approximately 1.4% of PANC-1 cells. Figure 1B summarizes a typical and representative time series both before and after MOMP. The morphologic changes (disappearance of distinct intracellular foci/appearance of diffuse cytosolic fluorescence) were readily visible and were used to identify MOMP via image analysis algorithm (Figs. 1B and 2B). The sequence of events leading up to irreversible cell death (MOMP, rounding, blebbing, nuclear fragmentation) was defined for both cell lines. However, as previously observed in HeLa cells (12), biologic variability was prevalent throughout the cell population. To better compare time scales of events and to provide statistics, we quantified these cell processes in real-time. For MDA-MB-231, ABT-263-induced MOMP at 135 ± 85 minutes (mean ± SD), rounding occurred at 61 ± 83 minutes, blebbing at 134 ± 77 minutes, and chromatin condensation at 173 ± 67 minutes; for PANC-1 cells, MOMP occurred at 363 ± 57 minutes, rounding at 291 ± 131 minutes, and blebbing at 386 ± 83 minutes.

**Characterization of in vivo tumors**

Although image analysis of sparsely plated cells in culture was relatively simple, in vivo analysis proved more complex due to cellular crowding. To enable easier identification of individual cells, a second fluorescent marker was introduced. For this, we selected H2B-FP, a nuclear histone protein, which when fused to a fluorescent protein can be used to identify chromatin condensation, a later step in the apoptotic pathway (1). We subsequently determined whether these tumors could grow in vivo, and if so how their growth and apoptotic rates compared with those in the in vitro environment.

Both MDA-MB-231-IMS/H2B and PANC-1-IMS/H2B cells grew well in xenografts, showing similar growth characteristics to the parental cell lines (Fig. 3). Both cell lines also grew readily in window chambers. At ×60 magnification, individual mitochondria could be easily discerned within individual cells in vivo (Fig. 3). We were thus able to verify that mitochondria have a similar appearance in vivo as in vitro. Furthermore, cells undergoing apoptosis in vivo could be easily identified using the dual fluorescent marker. One significant difference between our in vitro and in vivo measurements, however, was in the basal apoptosis rates of cells. For both cell lines tested, we observed higher apoptosis rates in vivo than in vitro (MDA-MB-231-IMS/H2B: 0.6% in vitro vs. 11.6% in vivo; PANC-1-IMS/H2B: 1.4% in vitro vs. 8.6% in vivo). These differences could be explained by the presence of selective pressures in the tumor microenvironment, which are not encountered in culture conditions.

The availability and use of both MOMP and chromatin condensation/fragmentation reporters were useful not only for identifying individual cells but also for temporarily assessing the apoptotic process (Fig. 4). Under basal state...
Measuring drug-induced apoptosis at the single-cell level 

in vivo

We next determined whether drug treatment effects could be monitored directly in vivo at the single-cell level (single-cell pharmacodynamics). To do this, we treated established tumors with the Bcl-2 inhibitor, navitoclax (ABT-263), a drug currently undergoing clinical trials both as a combination treatment (with docetaxel, paclitaxel, erlotinib, rituximab, gemcitabine, among others) and as a monotherapy. In parallel, and as a comparison, we carried out similar experiments in cell culture. We found that although a single dose of navitoclax (100 µmol/L) in vitro induced apoptosis in nearly all MDA-MB-231-IMS/H2B cells within a 5-hour period, it only induced apoptosis in approximately 20% of PANC-1-IMS/H2B cells under the same conditions (Fig. 5). These results are consistent with earlier findings, which showed that although EC₅₀ values for navitoclax ranged from 0.11 to 39 µmol/L in small cell lung cancer and hematologic cancer lines, most other solid tumors are not as responsive to navitoclax treatment alone (13, 14).

When tested in vivo, drug-induced apoptosis was readily identifiable. To approximately match the drug dose encountered by cells in vitro (15), 100 mg/kg of navitoclax was injected intraperitoneally into mice. Previous studies have determined this dose to be efficacious without inducing major thrombocytopenia (13, 16). Although the pancreatic and breast cancer cell lines showed divergent behavior in vitro, apoptosis rates of the cell lines in vivo were remarkably similar. Furthermore, apoptosis rates in vivo plateaued at approximately 20%, a 100% increase from basal levels. Our studies therefore indicate that both tumor types respond to navitoclax monotherapy in vivo. Apoptotic cells did not show any preferential distribution, either in their distance from the tumor microvessels or within the tumors themselves.

Comparison with exogenous stains

Drug-induced apoptosis is often measured via nongenetic means using fluorescent Annexin V or other affinity ligands (e.g., NucView). Although the Annexin V approach is particularly well-established in vitro, its validity in in vivo settings has not yet been explored at the single-cell level. We resolved to determine whether systemic injection of Annexin V in mice would result in its accumulation in apoptotic cells (defined by MOMP and chromosome condensation). Interestingly, we observed that nearly all fluorescently labeled Annexin V colocalized with tumor-associated macrophages (TAM) outside of the tumor rather than with apoptotic tumor cells (Fig. 6). Indeed, terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL)-stained apoptotic cells failed to show significant colocalization with Annexin V in vivo (Supplementary Fig. S2). We hypothesize that dying cancer cells recruit monocytes to the tumor site, where they differentiate into TAMs, and result in both cell types accumulating the imaging agent. Assessment of TAMs may therefore represent an indirect means for identifying cell death for some tumor types, reporting on the macrophage response rather than on apoptosis directly.

Figure 3. In vivo images of breast (top) or pancreatic (bottom) cancer cells expressing IMS and H2B reporter proteins in a live mouse. A, MDA-MB-231 cancer cells in vivo at high (left) and low (right) magnification. The white arrow points to a cell containing swollen mitochondria. B, PANC-1 cancer cells in vivo at high (left) and low (right) magnification. Arrows point to apoptotic blebs. Note the cellular detail achievable by in vivo imaging. Scale bars, 10 µm.

Figure 4. Percentage of apoptotic cells undergoing MOMP and/or chromatin condensation in treated and untreated tumors. Apoptosis typically involves caspase activation followed by MOMP and subsequent chromatin condensation. In vivo, cells are also then cleared by phagocytic cells. The percentage of apoptotic cells undergoing MOMP and/or chromatin condensation in treated and untreated tumors (n = 3 for each cell type) was assessed qualitatively. Images show examples of cells at each stage. The percentages show the number of cells under resting (~10% apoptosis) and ABT-263 treatment conditions (~20% apoptosis), and their respective distributions in the apoptotic cascade. MOMP-pos refers to cells undergoing MOMP only and Chromatin-pos refers to chromatin condensed/fragmented cells only. Observations in the treatment group were carried approximately 1 day after intraperitoneal injection of ABT-263.
Discussion

The use of high spatial resolution imaging has become widespread in cell biology. However, the attainment of similar resolutions in vivo has remained challenging because of motion, limited achievable signal-to-noise ratios, and restricted tissue penetration of light (17). In view of the findings showing that many cellular processes and responses can behave differently in vivo compared with in vitro, it is now clear that the ability to image at subcellular resolution in vivo would have important consequences. Here, we show not only that it is practically feasible to image apoptotic events within individual cells over time but also that it is possible to measure drug-induced effects in the living animal. These results are important for several reasons. First, such
technological advances will likely broaden the study of apoptosis and its regulation at both the single-cell and population-level in vivo. Second, the use of such a method could be applied as a tool in systems pharmacology for measuring the therapeutic effect (or failure) of drugs on individual cells, cell populations, or cell niches. Third, if and when combined with fluorescent drugs (18, 19), this approach could serve to improve our ability to map both the PK and PD of drugs. Similarly, the toxicity of drugs on nonmalignant cells could be determined in transgenic mice that express the reporters. Finally, our findings suggest the possibility that other cellular structures and pathways could similarly be imaged at high spatial resolutions in vivo.

Several studies have used intravital microscopy to study tumor immunology (20–22), microvascularity (23), and invasion and metastases (24–26), as well as cell-cycle progression (1, 17). Many of these studies, however, used lower resolutions to visualize cell–cell interactions or cellular movements over time. In our investigation, because our aim was to resolve intracellular details (not generally needed for cell tracking studies), we required much higher spatial resolutions. We achieved this by creating highly fluorescent dual reporter lines and then carefully optimizing the acquisition conditions. IMS-RP is a biologically neutral reporter that lacks the IAP-binding motif. As a result, there are no biologic side effects from overexpression of the Smac/DIABLO peptide (as there would from expression of full-length proteins fused to fluorescent proteins). Lentiviral constructs provide a rapid method for labeling cells, including primary cells. A major technical challenge in intravital microscopy, however, is overcoming artifacts caused by physiologic motion. In our study, to reduce motion during prolonged imaging sessions, the window chambers of isoflurane-anesthetized mice were immobilized on a heated stage, and the mice were monitored carefully throughout each experiment. Scan speeds were likewise adjusted to reduce artifacts. To obtain a 3-dimensional representation of the field of view, all images were collected as z-stacks using a high magnification water-immersion objective.

Despite numerous technological advances in intravital imaging, there remain a number of unresolved practical issues. First, to obtain the highest possible spatial resolution, capable of resolving mitochondria and chromatin within cells, this study required the use of window chamber models. In future research, it would be interesting to extend this type of imaging to the study of orthotopic cancers in genetically engineered mouse models. For this to be possible, however, better immobilization strategies and optics are needed. We nevertheless remain confident that with continuing advances in miniatureized optics (27, 28), fast scanning, and newer immobilization techniques, such studies will ultimately be feasible. A second area in need of improvement is in the design of reporter constructs. For example, the use of more red-shifted (29) or brighter fluorescent proteins would increase the signal-to-noise ratio and thus facilitate image analysis. Alternatively, the creation and use of turn-on fluorescent protein reporters that only fluoresce during apoptosis would be another interesting means of obtaining information about the signaling pathways involved in this process. Several caspase-activatable probes have recently been described for detection of cell death in vitro (3); but these have yet to be tested in vivo. Another area demanding significant attention is the development of automated image analysis and quantitation, particularly for use in unsupervised paradigms (30–32). Finally, there is an obvious need for deeper imaging into tumors. It is possible that this issue could be addressed through the use of multiphoton approaches, more red-shifted constructs, and perhaps newer illumination schemes (33).

The in vivo studies presented here not only complement earlier investigations in HeLa cells (2, 13, 34) but also serve to further validate these studies in breast and pancreatic cancer cell lines. Several important differences should nevertheless be highlighted. For example, Spencer and colleagues primarily used a combination of TRAIL and cycloheximide treatment to induce cell death. In cases where TRAIL was used alone, however, it seems the researchers required 5-fold greater concentrations of TRAIL to induce cell death, which is comparable with the concentration used in our study to induce cell death within a similar time frame. In addition, we also found that the duration of MOMP in both PANC-1 and MDAMB-231 cells was similar to that seen in HeLa cells (for both, it occurred in minutes). In this study, we used navitoclax rather than TRAIL to induce apoptosis on the basis that this drug is currently under investigation in clinical trials. Navitoclax (ABT-263) is a small-molecule inhibitor of the prosurvival Bcl-2 family of proteins, which include Bcl-2, Bcl-xl, and Mcl-1. From studies of small cell lung carcinoma and acute lymphoblastic leukemia, the reported effective dose range for navitoclax is approximately 110 nmol/L to 39 μmol/L (16). In our own experiments, although 25 μmol/L ABT-263 was sufficient to cause cell death in approximately 50% of MDA-MB-231 cells, it did not cause significant apoptosis in PANC-1 cells. We thus increased the in vitro dose of ABT-263 to 100 μmol/L.

In summary, we believe that by continuing to make advances in microscopic imaging and apoptotic reporter constructs, these tools could soon have broad applications for biology and drug development. We expect that the use of IMS-RP, together with other genetic reporters, will not only allow us to visualize multiple components of the apoptotic signaling pathways (which will likely differ depending on drug treatment/cell type) but also be useful for drug efficacy profiling. Naturally, such reporters will need to be applied to the study of other forms of drug-induced cell death, for example, by the creation of in vivo reporters for DNA damage (35), senescence (4), autophagy (5), and necrosis, among others (36).

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: S. Earley, R. Weissleder
Development of methodology: S. Earley, C. Vinegoni, R. Weissleder
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Earley, J. Dunham, R. Gorbatov
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Earley, C. Vinegoni, J. Dunham, P.F. Feruglio, R. Weissleder
Writing, review, and/or revision of the manuscript: S. Earley, C. Vinegoni, J. Dunham, P.F. Feruglio, R. Weissleder
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Earley, R. Gorbatov, R. Weissleder
Surgery: R. Gorbatov, R. Weissleder

Acknowledgments
The authors thank Drs. Kohler, Sergeyev, Fisher-Jeffes, Thubler, Yosheko Iwamoto, and all members of the Pettet Laboratory for valuable technical suggestions, review, and reagents. The authors also thank collaborators for their invaluable discussions: Drs. Timothy Mitchison (EB9 constructs), Peter Sorger (MS-FP constructs), Mikhail Piett, Anthony Letai, Gaudenz Danuser, and Charles Lain.

References

Grant Support
This work was supported in part by NIH grants: 2F50CA063555, 2RO1EB006432, 1PO1CA139980, 1RO1CA164448, and T32-CA74943.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 20, 2011; revised March 22, 2012; accepted April 4, 2012; published OnlineFirst April 13, 2012.
In Vivo Imaging of Drug-Induced Mitochondrial Outer Membrane Permeabilization at Single-Cell Resolution

Sarah Earley, Claudio Vinegoni, Joshua Dunham, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-4096

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/04/13/0008-5472.CAN-11-4096.DC1

Cited articles
This article cites 36 articles, 7 of which you can access for free at:
http://cancerres.aacrjournals.org/content/72/12/2949.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.